Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones
Me arrepentiré de no comprarla a estos precios ...
Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones
Que hijo puta
In a research report sent to investors today, Brean Capital analyst Jonathan Aschoffmaintained a NA rating on Threshold Pharmaceuticals (NASDAQ:THLD) with a price target of $15.00, which represents a potential upside of 377.7% from where the stock is currently trading.
Aschoff said, “We are dropping coverage of Threshold Pharmaceuticals, Inc. We are not optimistic about the prospects for the Phase 3 STS trial with TH-302 because a similar drug, Ziopharm’s (ZIOP; Not Rated) palifosfamide, failed in its Phase 3 STS trial in 1Q13. We have decided to allocate our research resources toward other companies that we view as having more investable catalysts. As such, our target price and rating for THLD should not be relied upon hereafter.”
-----------------------------------
no entiendo como despues de un FAST TRACK y tras 1,5 años despues del estudio fallido de ZIOP ( que no trata hipoxia ), este tipo viene ahora con estas siendo que ademas el 8 de Julio de este año ratificaron su PO a 15$ !!. no-lo-comprendo.
Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones
Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones
no se Ana, no habia visto hasta la fecha una retirada de cobertura. no veo nada profesional este movimiento.
Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones
Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones
2.800 acciones, nada